Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 20, 2025
Transactions
12
Purchases
3
Sales
9
Purchase value
$163.61K
Sale value
$2.28M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Kyle CarverChief Financial Officer
4
Filed Jul 10, 2026Period of report Jul 8, 20260001757072-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 8, 2026
Common StockF1
1,000
$13.26
$13.26K
60,335
Direct
Filing footnotes · 1
F1The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.
Filed Jul 8, 2026Period of report Jul 7, 20260001290976-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 7, 2026
Common StockF1F2
10,000
$13.30
$133.00K
10,000
Jeegar Pravinkumar PatelChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260002092017-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Janice Suzann DrewChief of Dev. Operations
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260002091053-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Luis C. PenaDirector · President & CEO
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001620548-26-000007
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
David E CohenDirector
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 2, 20260001347383-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Jeegar Pravinkumar PatelChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260002092017-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Luis C. PenaDirector · President & CEO
4Rule 10b5-1 plan disclosed
Filed Jun 3, 2026Period of report Jun 1, 20260001620548-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Kyle CarverChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 1, 2026Period of report May 28, 20260001757072-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Gregory S. MossChief Business & Legal Officer
4Rule 10b5-1 plan disclosed
Filed Jun 1, 2026Period of report May 28, 20260001742496-26-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Robert Lorne HopfnerDirector · 10% owner
4
Filed Dec 22, 2025Period of report Dec 19, 20250001012975-25-000937
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseDec 19, 2025
Common StockF1
1,000
$17.35
$17.35K
4,026
Indirect
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
IndirectBy Trust
Filing footnotes · 2
F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
F2One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026.
F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F1The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F2Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F4Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.